PEPTIDE ENHANCED ARTIFICIAL SKIN

肽增强人造皮肤

• 批准号: 2867600
• 负责人: FREDERICK CAHN
• 金额: $ 25.11万
• 依托单位: INTEGRA LIFESCIENCES CORPORATION
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-08-01 至 2001-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2867600
• 关键词: angiogenesis; artificial skin; biomaterial compatibility; biomaterial development /preparation; biomaterial evaluation; collagen; guinea pigs; histology; integrins; peptide chemical synthesis; peptides; swine; tissue engineering; wound healing

INTEGRA(R) Artificial Skin is a bilayer system that enables the replacement of injured skin with functional autologous tissue. This project is the logical next step in the perfection of this tissue engineered product. Following clinical trials and commercial introduction, we have been able to identify its strengths and weaknesses in the clinical setting. The strengths of this product include rapid physiological recovery during acute treatment, minimal donor site morbidity, and excellent functional outcome characterized by an absence of scarring. The weaknesses include a higher incidence of postoperative complications than for conventional autograft. Our hypothesis is that the advantage of autograft is due to endothelial cells from the vasculature in autograft. which allow the autograft to rapidly revascularize. Therefore, we postulate that the incidence of postoperative complications for Artificial Skin can be reduced by accelerating angiogenesis by our peptide enhancement technology. Peptide Enhanced Artificial Skin can be expected to promote a speedier rate of wound healing, which should result in a decreased incidence of complications, principally those arising from infection and mechanical dislodgment. In addition, we anticipate an improved cosmetic and functional outcome. In Phase I we will develop prototypes and demonstrate their biocompatibility and efficacy in animal models. PROPOSED COMMERCIAL APPLICATIONS: If this SBIR program is successful Integra LifeSciences Corporation is committed to manufacturing the Peptide Enhanced Artificial Skin and marketing it worldwide for burns and reconstructive surgery. Future applications may include chronic wounds. Potential Markets are over $800,000,000 per year. Sales of over $10,000,000 are projected within 2 years of introduction.

INTEGRA（R）人造皮肤是一种双层系统，能够用功能性自体组织替代受损皮肤。这个项目是这个组织工程产品完美的合乎逻辑的下一步。在临床试验和商业引入之后，我们已经能够确定其在临床环境中的优势和劣势。该产品的优势包括在急性治疗期间快速生理恢复，最小的供体部位发病率，以及以无瘢痕为特征的优异功能结局。缺点包括术后并发症的发生率高于传统自体移植。我们的假设是，自体移植的优势是由于内皮细胞从血管自体移植。使自体移植物迅速再血管化。因此，我们假设人工皮肤术后并发症的发生率可以通过我们的肽增强技术加速血管生成来降低。肽增强型人工皮肤有望促进伤口愈合速度加快，从而降低并发症的发生率，主要是由感染和机械移位引起的并发症。此外，我们预期外观和功能结局会得到改善。在第一阶段，我们将开发原型，并在动物模型中证明其生物相容性和有效性。拟议的商业应用：如果SBIR计划成功，Integra生命科学公司将致力于生产肽增强型人造皮肤，并在全球范围内销售，用于烧伤和重建手术。未来的应用可能包括慢性伤口。潜在市场每年超过8亿美元。预计在推出后的两年内销售额将超过10，000，000美元。